We are live on ! Find out more
FOLD

Amicus Therapeutics

Delisted

FOLD was delisted on the 24th of April, 2026.

141 hedge funds and large institutions have $1.75B invested in Amicus Therapeutics in 2017 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 44 increasing their positions, 44 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

143% more call options, than puts

Call options by funds: $31.4M | Put options by funds: $12.9M

47% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 19

46% more capital invested

Capital invested by funds: $1.2B → $1.75B (+$550M)

29% more funds holding in top 10

Funds holding in top 10: 79 (+2)

5% more funds holding

Funds holding: 134141 (+7)

3.61% more ownership

Funds ownership: 118.25%121.86% (+3.6%)

0% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 44

Holders
141
Holders Change
+7
Holders Change %
+5.22%
% of All Funds
3.51%
Holding in Top 10
9
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+28.57%
% of All Funds
0.22%
New
28
Increased
44
Reduced
44
Closed
19
Calls
$31.4M
Puts
$12.9M
Net Calls
+$18.5M
Net Calls Change
+$16.5M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$216M +$5.67M +705,153 +3%
PA
2
Perceptive Advisors
New York
$174M
RG
3
Redmile Group
California
$121M +$5.38M +668,080 +6%
BlackRock
4
BlackRock
New York
$119M -$1.49M -185,638 -2%
Vanguard Group
5
Vanguard Group
Pennsylvania
$91.8M +$3.46M +430,486 +5%
Jennison Associates
6
Jennison Associates
New York
$90M -$820K -101,909 -1%
PAI
7
Palo Alto Investors
California
$80M +$465K +57,800 +0.7%
Morgan Stanley
8
Morgan Stanley
New York
$73M +$9.02M +1,120,733 +18%
Janus Henderson Group
9
Janus Henderson Group
United Kingdom
$70.8M +$56.5M +7,027,010 New
Wellington Management Group
10
Wellington Management Group
Massachusetts
$60.3M +$5.23M +649,676 +12%
ACA
11
Avoro Capital Advisors
New York
$59.7M +$8.72M +1,083,379 +22%
State Street
12
State Street
Massachusetts
$59.3M +$1.01M +125,635 +2%
Victory Capital Management
13
Victory Capital Management
Texas
$44M -$4.74M -589,140 -12%
D.E. Shaw & Co
14
D.E. Shaw & Co
New York
$41M +$3.93M +488,357 +14%
SAM
15
Sectoral Asset Management
Quebec, Canada
$35.1M -$6.66M -827,706 -19%
FCM
16
Farallon Capital Management
California
$30.2M +$24.1M +3,000,000 New
T. Rowe Price Associates
17
T. Rowe Price Associates
Maryland
$28.3M -$217K -26,989 -0.9%
Citadel Advisors
18
Citadel Advisors
Florida
$28.3M +$11.4M +1,418,331 +102%
FM
19
Frazier Management
Washington
$26.2M
Franklin Resources
20
Franklin Resources
California
$19M
Point72 Asset Management
21
Point72 Asset Management
Connecticut
$18.9M -$9.07M -1,127,400 -38%
Northern Trust
22
Northern Trust
Illinois
$17.5M +$423K +52,569 +3%
AG
23
Artal Group
Luxembourg
$14.1M -$4.02M -500,000 -26%
Axa
24
Axa
France
$13.4M -$6.77M -840,815 -39%
JP Morgan Chase
25
JP Morgan Chase
New York
$12.9M -$1.48M -184,281 -13%

FOLD Hedge Fund Activity: Q2 2017 in Review

141 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q2 2017, worth a combined $1.75B — up 46% from $1.2B a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new FOLD positions and 19 closed out — a net gain of 9 holders — while 44 added to existing stakes and 44 trimmed.

The largest buyer was Janus Henderson Group, opening a new position worth an estimated $56.5M. The largest seller was Point72 Asset Management, cutting an estimated $9.07M.

  • 141 institutional investors held Amicus Therapeutics (FOLD) as of Q2 2017, up from 134 in Q1 2017.
  • Funds reported $1.75B of Amicus Therapeutics stock for Q2 2017, up 46% quarter-over-quarter.
  • 28 funds opened new Amicus Therapeutics positions in Q2 2017 and 19 closed out, a net change of +9 holders.
  • The largest Amicus Therapeutics buyer in Q2 2017 was Janus Henderson Group, an estimated $56.5M added.
  • The largest Amicus Therapeutics seller in Q2 2017 was Point72 Asset Management, an estimated $9.07M sold.

Based on aggregated 13F filings for Q2 2017.